94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Bioeng. Biotechnol.
Sec. Nanobiotechnology
Volume 13 - 2025 | doi: 10.3389/fbioe.2025.1547025
This article is part of the Research Topic Development of mRNA Vaccines for Prevention and Therapy of Infectious and Oncological Diseases View all articles
mRNA vaccine platforms: Linking infectious disease prevention and cancer immunotherapy
Provisionally accepted
Dariush Haghmorad 1*
Majid Eslami 1 Niloufar Orooji 1
Iryna Halabitska 2 Iryna Kamyshna 2
Oleksandr Kamyshnyi 2*
Valentyn Oksenych 3*- 1 Semnan University of Medical Sciences, Semnan, Semnan, Iran
- 2 Ternopil State Medical University, Ternopil, Ternopil Oblast, Ukraine
- 3 University of Bergen, Bergen, Norway
The advent of mRNA vaccines, accelerated by the global response to the COVID-19 pandemic, marks a transformative shift in vaccine technology. In this article, we discuss the development, current applications, and prospects of mRNA vaccines for both the prevention and treatment of infectious diseases and oncology.By leveraging the capacity to encode antigens within host cells directly, mRNA vaccines provide a versatile and scalable platform suitable for addressing a broad spectrum of pathogens and tumor-specific antigens.We highlight recent advancements in mRNA vaccine design, innovative delivery mechanisms, and ongoing clinical trials, with particular emphasis on their efficacy in combating infectious diseases, such as COVID-19, Zika, and influenza, as well as their emerging potential in cancer immunotherapy. We also address critical challenges, including vaccine stability, optimization of immune responses, and the broader issue of global accessibility. Finally, we review potential strategies for advancing next-generation mRNA vaccines, with the aim of overcoming current limitations in vaccine technology and enhancing both preventive and therapeutic approaches for infectious and oncological diseases.
Keywords: mRNA vaccines, infectious diseases, cancer immunotherapy, vaccine development, Vaccine delivery systems
Received: 17 Dec 2024; Accepted: 24 Feb 2025.
Copyright: © 2025 Haghmorad, Eslami, Orooji, Halabitska, Kamyshna, Kamyshnyi and Oksenych. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Dariush Haghmorad, Semnan University of Medical Sciences, Semnan, 56131-56491, Semnan, Iran
Oleksandr Kamyshnyi, Ternopil State Medical University, Ternopil, 46002, Ternopil Oblast, Ukraine
Valentyn Oksenych, University of Bergen, Bergen, Norway
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.